An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7-Day Triple Therapy With Bismuth Versus 14-Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents.

Helicobacter · 2026 · PMC12776654 · PMID 41498301

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

A decreasing trend was observed for all adverse events, with the most pronounced decline seen in nausea. 5 Discussion This study, conducted in a cohort of treatment‐naïve children, observed higher eradication rates with a 7 day triple therapy with bismuth (ITT: 91%; PP: 94%) compared to the 14‐day standard triple therapy (ITT and PP: 87%).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.